Using human growth hormone (somatropin)

Short stature was first treated in 1958 with growth hormone (GH) made from human pituitary glands.1 In 1985 biosynthetic GH was introduced after several young adults treated with GH in childhood had died from Creutzfeldt-Jakob disease.2 The first biosynthetic GH somatrem (Somatonorm - KabiVitrum) contains an additional methionyl residue and is licensed for treating short stature of Turner’s syndrome as well as GH deficiency. A preparation identical to human GH is now available (somatropin (rbe); Genotropin - KabiVitrum). Who should have it?

Download Full-text

IMMUNOCHEMICAL STUDIES OF HUMAN PITUITARY GROWTH HORMONE

Acta Endocrinologica ◽

10.1530/acta.0.0400311 ◽

1962 ◽

Vol 40 (2) ◽

pp. 311-320 ◽

Cited By ~ 8

Author(s):

Zvi Laron ◽

Sara Assa

Keyword(s):

Growth Hormone ◽

Human Growth Hormone ◽

Haemagglutination Inhibition ◽

Rabbit Antiserum ◽

Human Growth ◽

Human Albumin ◽

Agar Gel ◽

Human Pituitary ◽

Pituitary Glands ◽

Fraction I

ABSTRACT Human growth hormone (HGH) prepared from human pituitary glands by the method of Raben (1959) showed two components on agar gel electrophoresis. Fraction I corresponded to a slow alpha-globulin, and fraction II had a mobility between alpha and beta-globulin. On agar gel immunoelectrophoresis using HGH and rabbit antiserum to HGH, these two components showed immunological identity. By using agar gel immunoelectrophoresis and the haemagglutination technique HGH preparations of both Raben and Li type were shown to be contaminated with human albumin. Antiserum to human growth hormone containing also antibodies against human albumin was purified by adsorption with human albumin. It is postulated that part of the difficulties encountered in the use of the haemagglutination-inhibition technique to determine growth hormone concentration in serum, is due to impurities in the human growth hormone preparations and antisera to these preparations in use.

Download Full-text

RADIOIMMUNOASSAY STUDIES WITH HUMAN GROWTH HORMONE AND A PITUITARY LIPID MOBILIZING FACTOR

Acta Endocrinologica ◽

10.1530/acta.0.0580318 ◽

1968 ◽

Vol 58 (2) ◽

pp. 318-338 ◽

Cited By ~ 16

Author(s):

N. Norman ◽

Aa. R. Turter

Keyword(s):

Growth Hormone ◽

Human Growth Hormone ◽

Antibody Formation ◽

Human Growth ◽

Structural Features ◽

The Other ◽

Human Pituitary ◽

Pituitary Glands ◽

Growth Promoting ◽

The One

ABSTRACT A description is given of a radioimmunoassay procedure for human growth hormone (HGH). Particular emphasis is placed on problems encountered with aggregation and unspecific serum protein binding of the 125I radioiodinated HGH. Immunization of rabbits and guinea pigs with a highly purified lipid mobilizing factor (LMF) from human pituitary glands was attempted. This did not result in antibody formation towards LMF, but gave high titers against HGH. The observation thus suggests that LMF may have structural features in common with the HGH molecule. The antibody towards HGH may, however, also have been produced by a minimal contamination with HGH in the LMF. It was shown that detectable antibody formation towards HGH could be produced in rabbits with as little as 5 μg HGH. During the study of two highly purified HGH preparations – the one containing only growth promoting or somatotrophic activity, the other had adipokinetic activity as well - it was shown that the employed radioimmunoassay is specifically directed against the growth promoting part of HGH. Changes in the serum concentration of a possible physiologically acting LMF could therefore not be recorded, neither by a direct assay nor indirectly. On the other hand, the specificity of the HGH assay towards the »somatotrophin proper« assures that it is indeed this hormone that varies in concentration in response to insulin hypoglycaemia, exercise and postprandially. The stress of acute cardiac infarction did not increase growth hormone in the blood.

Download Full-text

The Effects of Recombinant Human Growth Hormone on Linear Growth in Children with Crohn's Disease and Short Stature

Journal of Pediatric Endocrinology and Metabolism ◽

10.1515/jpem.2007.20.12.1315 ◽

2007 ◽

Vol 20 (12) ◽

Cited By ~ 10

Author(s):

S C. Wong ◽

K. Hassan ◽

P. McGrogan ◽

L.T. Weaver ◽

S.F. Ahmed

Keyword(s):

Growth Hormone ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Short Stature ◽

Human Growth Hormone ◽

Linear Growth ◽

Recombinant Human Growth Hormone ◽

Human Growth

Download Full-text

The effect of treatment with recombinant human growth hormone (rhGH) on linear growth and adult height in children with idiopathic short stature (ISS): a systematic review and meta-analysis

Journal of Pediatric Endocrinology and Metabolism ◽

10.1515/jpem-2020-0287 ◽

2020 ◽

Vol 33 (12) ◽

pp. 1577-1588

Author(s):

George Paltoglou ◽

Ioannis Dimitropoulos ◽

Georgia Kourlaba ◽

Evangelia Charmandari

Keyword(s):

Systematic Review ◽

Growth Hormone ◽

Short Stature ◽

Human Growth Hormone ◽

Adult Height ◽

Linear Growth ◽

Meta Analysis ◽

Recombinant Human Growth Hormone ◽

Human Growth ◽

Idiopathic Short Stature

AbstractObjectivesIdiopathic short stature (ISS) is a recognized, albeit a controversial indication for treatment with recombinant human growth hormone (rhGH).The objective of the present study was to conduct a systematic review of the literature and meta-analyses of selected studies about the use of rhGH in children with ISS on linear growth and adult height (AH).MethodsA systematic literature search was conducted to identify relevant studies published till February 28, 2017 in the following databases: Medline (PubMed), Scopus and Cochrane Central Registry of Controlled Trials. After exclusion of duplicate studies, 3,609 studies were initially identified. Of those, 3,497 studies were excluded during the process of assessing the title and/or the abstract. The remaining 112 studies were evaluated further by assessing the full text; 21 of them fulfilled all the criteria in order to be included in the current meta-analysis.ResultsChildren who received rhGH had significantly higher height increment at the end of the first year, an effect that persisted in the second year of treatment and achieved significantly higher AH than the control group. The difference between the two groups was equal to 5.3 cm (95% CI: 3.4–7 cm) for male and 4.7 cm (95% CI: 3.1–6.3 cm) for female patients.ConclusionIn children with ISS, treatment with rhGH improves short-term linear growth and increases AH compared with control subjects. However, the final decision should be made on an individual basis, following detailed diagnostic evaluation and careful consideration of both risks and benefits of rhGH administration.

Download Full-text